Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel: CNS Lymphoma

Explore the latest updates and expert interviews

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos. The supporters have no influence over the production of the content.

Welcome to The CNS Lymphoma Channel

VJHemOnc brings you the most up-to-date developments within CNS lymphoma from key international congresses, where we offer exclusive video interviews, podcasts, and roundtable discussions with leading experts. The CNS Lymphoma Channel provides insightful perspectives on the latest trial updates and real-world data in CNS lymphoma.

The prognostic significance and therapeutic potential of the TLR 7/8 pathway in CNS lymphomas 6:42
The prognostic significance and therapeutic potential of the TLR 7/8 pathway in CNS lymphomas
James Rubenstein • 19 Jun 2025
The future of primary CNS lymphoma treatment: BTK-targeting agents and immunotherapy 2:49
The future of primary CNS lymphoma treatment: BTK-targeting agents and immunotherapy
Lakshmi Nayak • 19 Jun 2025
The Phase II PROSPECT trial: the efficacy and safety of tirabrutinib in R/R primary CNS lymphoma 3:16
The Phase II PROSPECT trial: the efficacy and safety of tirabrutinib in R/R primary CNS lymphoma
Lakshmi Nayak • 19 Jun 2025
MB-CART19.1 cell therapy for R/R CD19+ hematological malignancies with CNS involvement 5:03
MB-CART19.1 cell therapy for R/R CD19+ hematological malignancies with CNS involvement
Skirmante Cernauskiene • 20 Jun 2025
Comparing consolidation options in CNS lymphoma: autoSCT & reduced-dose whole-brain radiation 4:01
Comparing consolidation options in CNS lymphoma: autoSCT & reduced-dose whole-brain radiation
Kathryn Tringale • 12 Jun 2025
Key challenges associated with treating CNS lymphomas & advice for community oncologists 2:45
Key challenges associated with treating CNS lymphomas & advice for community oncologists
Kathryn Tringale • 12 Jun 2025
Ongoing research in the field of CNS lymphoma: improving patient outcomes & reducing toxicities 3:00
Ongoing research in the field of CNS lymphoma: improving patient outcomes & reducing toxicities
Kathryn Tringale • 12 Jun 2025
The PRiZM+ platform study for R/R primary CNS lymphoma: first results with zanubrutinib monotherapy 2:15
The PRiZM+ platform study for R/R primary CNS lymphoma: first results with zanubrutinib monotherapy
Christopher Fox • 18 Jun 2025
Looking to the future of CNS lymphoma management 1:36
Looking to the future of CNS lymphoma management
Andrés Ferreri • 28 Feb 2025
Unmet clinical needs in CNS lymphomas: older patients and chemorefractory disease 1:49
Unmet clinical needs in CNS lymphomas: older patients and chemorefractory disease
Andrés Ferreri • 28 Feb 2025
The management and subgrouping of CNS lymphomas 3:33
The management and subgrouping of CNS lymphomas
Andrés Ferreri • 28 Feb 2025
Findings from a Phase I trial of the BTK degrader NX-5948 in B-cell malignancies 1:05
Findings from a Phase I trial of the BTK degrader NX-5948 in B-cell malignancies
Talha Munir • 8 Dec 2024
The changing landscape of BTK-targeted therapies for B-cell lymphomas and CLL 0:58
The changing landscape of BTK-targeted therapies for B-cell lymphomas and CLL
Juan Alderuccio • 8 Dec 2024
Evolution of the treatment landscape for patients with CNS lymphoma 0:53
Evolution of the treatment landscape for patients with CNS lymphoma
Lakshmi Nayak • 2 Jun 2024
The current SoC for patients with primary CNS lymphoma 2:32
The current SoC for patients with primary CNS lymphoma
Lakshmi Nayak • 2 Jun 2024
Liquid biopsy to diagnose CNS lymphoma and monitor treatment response 4:20
Liquid biopsy to diagnose CNS lymphoma and monitor treatment response
Lakshmi Nayak • 2 Jun 2024

The Lymphoma Channel on VJHemOnc is supported by AstraZeneca, Takeda and Galapagos.

The supporters have no influence over the production of the content.

If you are interested in becoming a supporter of The Lymphoma Channel, please contact us.

Choose your cookie settings

VJHemOnc uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJHemOnc is intended for healthcare professionals